Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eptinezumab - Lundbeck Seattle BioPharmaceuticals

Next Previous
Drug Profile

Eptinezumab - Lundbeck Seattle BioPharmaceuticals

Alternative Names: ALD-403; Eptinezumab-jjmr; Lu-AG09221; VYEPTI

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alder Biopharmaceuticals
  • Developer Lundbeck A/S; Lundbeck Seattle BioPharmaceuticals Inc.
  • Class Analgesics; Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Migraine
  • Phase III Cluster headache

Most Recent Events

  • 05 Oct 2023 Lundbeck completes phase III ALLEVIATE trials in Cluster headache in United Kingdom, Sweden, Spain, Russia, Portugal, Norway, Greece, Germany, Georgia, France, Finland, Estonia, Denmark, Czech Republic, Belgium, Netherlands(NCT04688775; EudraCT2020-001969-37)
  • 21 Aug 2023 Lundbeck completes a phase I trial in Migraine (Prevention, In children, In adolescents) in USA (IV) (NCT04537429)
  • 29 Jun 2023 Lundbeck completes a phase III CHRONICLE trial in chronic cluster headache in Denmark, Italy, Finland, France, Germany, the Netherlands, Spain, united Kingdom and USA (NCT05064397)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top